Loreclezole ( —— )

产品货号. M20110 CAS No. 117857-45-1

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

产品询价大包装询价加入购物车

产品名称

Loreclezole
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

Loreclezole 是一种选择性 GABAA 受体调节剂，可作为含有 β2 或 β3 亚基的受体的正变构调节剂。
产品描述

Loreclezole is a selective GABAA receptor modulator and acts as a positive allosteric modulator of β2 or β3-subunit-containing receptors.
体外实验

——
体内实验

Loreclezole (10, 25, 50 or 75 mg/kg, i.p. 60 min before measurement of seizure threshold ) results in a dosedependent rise in seizure threshold as measured by the dose of pentylenetetrazolrequired to produce a convulsion 60 min later. Loreclezole also has the least effect on loss of muscle tone as measured by the “pull-up” test. Animal Model:Adult male Lister Hooded rats.Dosage:10, 25, 50 or 75 mg/kg.Administration:IP, 60 min before measurement of seizure threshold.Result:Resulted in a dosedependent rise in seizure threshold as measured by the dose of pentylenetetrazolrequired to produce a convulsion 60 min later.
同义词

——
通路

Others
靶点

Other Targets
受体

GABAA
研究领域

——
适应症

——

1.Donnelly JL et al. Loreclezole enhances apparent desensitization of recombinant GABAA receptor currents. Neuropharmacology. 1996;35(9-10):1233-41.

计算器

产品手册

关联产品

IGF-I (24-41) TFA (1...

IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).IGF-I (24-41) (TFA) is amino acids 24 to 41 fragment of Insulin-like Growth Factor I (IGF-I).
2-Methoxystypandrone

2-Methoxystypandrone displays an immunomodulatory effect in a cellular model, it blocks inflammatory responses by impairing NF-?oB signaling to limit the inflammation and oxidative stress for preservation of BBB integrity.
BI-0474

BI-0474 是一种强效的 KRASG12C 抑制剂，其对 GDP-KRAS::SOS1 蛋白-蛋白相互作用的IC50 值为 7.0 nM。BI-0474 对携带 G12C 突变的 NCI-H358 细胞具有较好的抗增殖活性。BI-0474 还在非小细胞肺癌异种移植模型中显示出较好的抗肿瘤活性。